ARRY-502

DB16053InvestigationalSmall molecule

ARRY-502 is under investigation in clinical trial NCT01561690 (A Study of ARRY-502 in Patients With Persistent Asthma).

Mechanism: Pharmacologically active on Prostaglandin D2 receptor 2
Curator reviewed
Formula / weight: C₂₆H₂₃Cl₂NO₆ · 516.37 g/mol (avg)
Code names: ARRY-502

Resolves to

Compound

Structure

InChIKeyQIDYUNXQPQEJEC-IBGZPJMESA-NSMILESCOC1=CC(Cl)=CC=C1CCNC(=O)C1=CC=C(OC2=CC3=C(C=C2Cl)[C@H](CCO3)C(O)=O)C=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with ARRY-502, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.